EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Dupilumab‐associated ocular surface disease is characterized by a shift from Th2/Th17 toward Th1/Th17 inflammation

Kathrin Thormann iD, Anne-Sophie Lüthi, Felix Deniau, Anja Heider, Simone Cazzaniga iD, Susanne Radonjic-Hoesli iD, Mathias Lehmann, Christoph Schlapbach iD, Elio L Herzog, Marco Kreuzer, Martin S Zinkernagel iD, Cezmi A Akdis iD und 3 weitere

Allergy · 2024-04 · 79 (4) · 937-948

DOI: 10.1111/all.16045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergy, online erschienen am 05.02.2024. Verfasst von Kathrin Thormann und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Eye Diseases, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dupilumab is used for the treatment of atopic dermatitis (AD). Approximately one third of AD patients develop a dupilumab‐associated ocular surface disease (DAOSD), of which the pathomechanism is poorly understood. This study aimed at investigating inflammatory markers in tear fluids of patients on dupilumab therapy.

Methods

Tear fluids were collected from AD patients with DAOSD (ADwDAOSD), AD patients without DAOSD (ADw/oDAOSD), and non‐AD patients before and during dupilumab therapy, and analyzed using a specialized proteomic approach quantifying inflammatory markers. The ocular surface microbiome was determined by next generation sequencing technology.

Results

Upon dupilumab therapy, an upregulation of 31 inflammatory markers was observed in DAOSD tear fluids compared to baseline in AD patients. While IL‐12B was upregulated in both ADwDAOSD and ADw/oDAOSD groups, the pattern of inflammatory markers significantly differed between groups and over time. In the ADwDAOSD group, a shift from a mixed Th2/Th17 pattern at baseline toward a Th1/Th17 profile under dupilumab was observed. Furthermore, an upregulation of remodeling and fibrosis markers was seen in DAOSD. Semantic map and hierarchical cluster analyses of baseline marker expression revealed four clusters distinguishing between AD and non‐AD as well as ADwDAOSD and ADw/oDAOSD patient groups. In a pilot study, dupilumab therapy was associated with a decrease in richness of the ocular surface microbiome.

Conclusions

DAOSD is characterized by a Th1/Th17 cytokine profile and an upregulation of markers known to promote remodeling and fibrosis. The expression pattern of inflammatory markers in tear fluids at baseline might serve as a prognostic factor for DAOSD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicEye DiseasesAntibodies, Monoclonal, HumanizedHumansPilot ProjectsProteomicsInflammationFibrosisSeverity of Illness IndexTreatment Outcome

Stichwörter der Autor:innen

atopic dermatitisdry eye diseasedupilumabocular surface diseaseremodelingtype 1 inflammation

Substanzen

dupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland.
  • Centro Studi GISED, Bergamo, Italy.
  • Department for BioMedical Research, University of Bern, Bern, Switzerland.
  • Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland.

ORCID-Profile: Kathrin Thormann, Simone Cazzaniga, Susanne Radonjic-Hoesli, Christoph Schlapbach, Martin S Zinkernagel, Cezmi A Akdis, Denise C Zysset-Burri, Hans-Uwe Simon, Dagmar Simon

Zitieren

APA

Thormann, K., Lüthi, A. S., Deniau, F., Heider, A., Cazzaniga, S., Radonjic-Hoesli, S., Lehmann, M., Schlapbach, C., Herzog, E. L., Kreuzer, M., Zinkernagel, M. S., Akdis, C. A., Zysset-Burri, D. C., Simon, H. U., & Simon, D. (2024). Dupilumab‐associated ocular surface disease is characterized by a shift from Th2/Th17 toward Th1/Th17 inflammation. Allergy, 79(4), 937-948. https://doi.org/10.1111/all.16045

Vancouver

Thormann K, Lüthi AS, Deniau F, Heider A, Cazzaniga S, Radonjic-Hoesli S, et al. Dupilumab‐associated ocular surface disease is characterized by a shift from Th2/Th17 toward Th1/Th17 inflammation. Allergy. 2024;79(4):937-948. doi:10.1111/all.16045

BibTeX
@article{Thormann2024,
  author = {Thormann, Kathrin and Lüthi, Anne-Sophie and Deniau, Felix and Heider, Anja and Cazzaniga, Simone and Radonjic-Hoesli, Susanne and Lehmann, Mathias and Schlapbach, Christoph and Herzog, Elio L and Kreuzer, Marco and Zinkernagel, Martin S and Akdis, Cezmi A and Zysset-Burri, Denise C and Simon, Hans-Uwe and Simon, Dagmar},
  title = {Dupilumab‐associated ocular surface disease is characterized by a shift from Th2/Th17 toward Th1/Th17 inflammation},
  journal = {Allergy},
  year = {2024},
  volume = {79},
  number = {4},
  pages = {937--948},
  doi = {10.1111/all.16045}
}
Kostenlos starten →